Port, I agree there is some excellent buying to be had in biotech. I have no doubt that Biota's pipeline will allow it to prosper in due course, notwithstanding its poor management.
However, Neuren is the stand out for mine in terms of potential bang for your buck with Phase 3 results coming soon.
Add to My Watchlist
What is My Watchlist?